KZIA - KAZIA THERAPEUTICS LTD

8.25
-0.260   -3.152%

Share volume: 134,303
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$8.51
-0.26
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-6.57%
1 Month
44.23%
3 Months
-47.52%
6 Months
1.85%
1 Year
599.15%
2 Year
3,651.71%
Key data
Stock price
$8.25
P/E Ratio 
0.00
DAY RANGE
$7.90 - $8.62
EPS 
N/A
52 WEEK RANGE
$0.60 - $17.40
52 WEEK CHANGE
$768.70
MARKET CAP 
11.159 M
YIELD 
N/A
SHARES OUTSTANDING 
26.362 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
2.29
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$233,308
AVERAGE 30 VOLUME 
$206,743
Company detail
CEO: James S. Garner
Region: US
Website: kaziatherapeutics.com
Employees: 12
IPO year: 1999
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Kazia Therapeutics Limited is an oncology-focused biotechnology company. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway. It is also developing EVT801, an investigational new drug for various forms of cancer.

Recent news